Literature DB >> 18296903

Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

P A Essah1, J E Nestler, E Carmina.   

Abstract

BACKGROUND: Dyslipidemia is a common metabolic complication in polycystic ovary syndrome (PCOS). The aim of this study was to determine if differences exist in dyslipidemia in women with PCOS from different ethnic and geographical backgrounds.
METHODS: This retrospective study evaluated the serum fasting lipid profiles of 106 women with PCOS from the United States and 108 women with PCOS from Italy evaluated at endocrinology clinics.
RESULTS: American women had higher mean body mass index than Italian women (36.1+/-8.6 vs 28.1+/-5.8 kg/m2, p<0.01). Low HDL-cholesterol was the most prevalent lipid abnormality in both populations. U.S. women had higher mean levels of serum total cholesterol, LDL-cholesterol, and triglycerides, and lower mean serum HDL-cholesterol. Most of these differences were due to differences in weight. After controlling for differences in weight and age, fasting serum triglycerides remained higher in U.S. women compared with Italian women [131.1 mg/dl, SE=7.8, 95% confidence interval =(115.7, 146.5) vs 99.3, SE=8.4, 95% confidence interval =(82.9, 115.8)].
CONCLUSIONS: Variations in body weight alone do not fully explain differences in dyslipidemia in women of diverse ethnic and geographical backgrounds. Genetic and environmental factors, such as diet and activity level, likely contribute to these differences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18296903     DOI: 10.1007/BF03345564

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

Review 1.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women.

Authors:  M J Graf; C J Richards; V Brown; L Meissner; A Dunaif
Journal:  Clin Endocrinol (Oxf)       Date:  1990-07       Impact factor: 3.478

4.  LDL size in African Americans, Hispanics, and non-Hispanic whites : the insulin resistance atherosclerosis study.

Authors:  S M Haffner; R D'Agostino; D Goff; B Howard; A Festa; M F Saad; L Mykkänen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

Review 5.  Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women.

Authors:  E Carmina; R A Lobo
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

6.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.

Authors:  Paul M Ridker; Nader Rifai; Nancy R Cook; Gary Bradwin; Julie E Buring
Journal:  JAMA       Date:  2005-07-20       Impact factor: 56.272

7.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  R A Wild; P C Painter; P B Coulson; K B Carruth; G B Ranney
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

8.  Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study.

Authors:  T Tillin; N Forouhi; D G Johnston; P M McKeigue; N Chaturvedi; I F Godsland
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

9.  Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.

Authors:  C J Glueck; Ranganath Papanna; Ping Wang; Naila Goldenberg; Luann Sieve-Smith
Journal:  Metabolism       Date:  2003-07       Impact factor: 8.694

10.  Cholesterol and coronary heart disease: predicting risks by levels and ratios.

Authors:  B Kinosian; H Glick; G Garland
Journal:  Ann Intern Med       Date:  1994-11-01       Impact factor: 25.391

View more
  18 in total

1.  Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.

Authors:  M Rizzo; R A Longo; E Guastella; G B Rini; E Carmina
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

Review 2.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

3.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

Review 4.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 5.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

6.  Association study between FSHR Ala307Thr and Ser680Asn variants and polycystic ovary syndrome (PCOS) in Northern Chinese Han women.

Authors:  Lingyuan Fu; Zhaofeng Zhang; Aiping Zhang; Jianhua Xu; Xianliang Huang; Qiupeng Zheng; Yunlei Cao; Lei Wang; Jing Du
Journal:  J Assist Reprod Genet       Date:  2013-03-29       Impact factor: 3.412

Review 7.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 8.  Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  E Carmina
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

9.  Lifestyle changes in women with polycystic ovary syndrome.

Authors:  Siew S Lim; Samantha K Hutchison; Emer Van Ryswyk; Robert J Norman; Helena J Teede; Lisa J Moran
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28

Review 10.  Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.